A cute pulmonary embolism (PE) is a potentially life-threatening manifestation of venous thromboembolism (VTE), the third most frequent acute cardiovascular syndrome, which affects between 75 and 269 individuals per 100,000 population around the world each year (2). It may appear reassuring that case fatality rates of PE have dropped over the past decades, possibly reflecting, among others, increased awareness of the disease and progress in management strategies (reviewed in [3]). However, the rising tendency in annual PE incidence (4,5) and PE-related mortality (6,7) in the population underlines the magnitude of the threat to ageing societies, and to the growing number of vulnerable patients with multiple predisposing factors for venous thrombosis and thromboembolism (2). Today, prompt institution of parenteral or oral anticoagulation remains the only universally recommended, truly “evidence-based” VTE treatment and PE prevention (8–10). On the other hand, reperfusion

中文翻译：

---

下腔静脉滤器预防肺栓塞的难以捉摸的证据*

可爱的肺栓塞 (PE) 是静脉血栓栓塞 (VTE) 的潜在危及生命的表现，VTE 是第三大常见的急性心血管综合征，每年影响全球每 100,000 人口 75 至 269 人 (2)。在过去的几十年中，PE 的病死率有所下降，这似乎令人欣慰，这可能反映了人们对该疾病认识的提高和管理策略的进步（见 [3] 中的综述）。然而，人口中每年 PE 发病率 (4,5) 和 PE 相关死亡率 (6,7) 的上升趋势突显出对老龄化社会和越来越多的易感患者的威胁程度，这些患者具有多种易感因素静脉血栓形成和血栓栓塞（2）。今天，及时进行胃肠外或口服抗凝治疗仍然是唯一普遍推荐的、真正“循证”的 VTE 治疗和 PE 预防 (8-10)。另一方面，再灌注